News

News

05/15/20

Aerospace to cellular therapy: How GID BIO’s CEO used his expansive engineering background to help design a scalable device for cellular therapy

An interview with William W. Cimino, Ph.D.   The beginning Ten years ago, the founders of GID were looking for a CEO. They made the connection between cell therapy, fat tissue and your background but you didn’t think you were the right person. What happened next?  I didn’t think I was a strong fit because I saw the position as requiring a significant background in cell biology, which I didn’t have....

Learn More

News

04/17/20

Beyond knee osteoarthritis: GID explores cellular therapy to potentially treat dermal, organ and more musculoskeletal diseases

From the bark of the willow tree 3,500 years ago that Egyptians and Sumerians popularized for pain relief, medicine is one industry that can be counted on for constant innovation over the centuries. Today, cellular therapy is the pillar of modern medicine, building on drugs and devices/surgery that have dominated medical care for the last 200 years. Cellular therapy is precision medicine and propels forward numerous paths to potentially treat...

Learn More

News

03/30/20

GID BIO addresses a growing need for cost-effective U.S. osteoarthritis treatments

The number of total knee replacement (TKR) surgeries is increasing annually, leaving experts concerned that by 2030 there may not be enough orthopedic surgeons to handle the growth. Existing alternatives to manage pain for patients with knee osteoarthritis include hyaluronic acid (HA) injections or corticosteroid (CS) injections which may be toxic to cartilage according to a Radiology report. Chris Schenk, a San Antonio realtor and avid tennis player, tried an...

Learn More

News

03/2/20

American Journal of Sports Medicine publishes results of a clinical trial for treating osteoarthritis knee pain

Trial measures safety and efficacy of device and point-of-care cellular therapy to help reduce pain and improve function in osteoarthritic knees   Louisville, Colo., New Orleans, San Antonio, Chicago – March 2, 2020 /PRNewswire/ -- GID BIO announced today that The American Journal of Sports Medicine published results of its multi-site, randomized, placebo-controlled Phase IIb clinical trial measuring the safety and efficacy of its SVF-2 device and point-of-care (POC) therapy intended...

Learn More

News

01/20/20

GID BIO seeks up to USD 25m to support cellular therapy platform, CEO says

Mergermarket is the leading provider of forward-looking M&A intelligence and data to investment banks, private equity firms, law firms, accounting firms, corporates and other M&A professionals around the world. WWW.MERGERMARKET.COM January 16, 2020 by Deb Balshem   GID BIO, a privately held cellular therapy company, is looking to raise between USD 20m and USD 25m to support a pivotal Phase 3 trial and potential commercialization, said CEO William Cimino. Louisville,...

Learn More

News

01/18/20

An interview with William Cimino, PhD, CEO GID BIO, International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France

GID BIO CEO William Cimino, PhD sat down with SmartTRAK, BioMedGPS Senior Analyst, Regenerative Medicine at the International Federation for Adipose Therapeutics and Science (IFATS) Annual Conference in Marseille, France. Click here to listen to the full interview.

Learn More

News

01/17/20

Physicians: advancing the future of evidence-based cellular therapy could increase quality of life for 14 million US adults suffering from knee osteoarthritis

Over the past three decades cardiothoracic procedures have significantly shifted to minimally invasive techniques with new technology, training of physicians and an ecosystem for workforce development. Orthopedics is on the forefront of a similar shift. Fourteen million U.S. adults suffer from knee osteoarthritis and professional athletes are driving a demand for alternative treatments to surgery, despite many being unsupported by data and lacking proof of success. This level of patient...

Learn More

News

01/14/20

Leaders come together for the first time to advance the field of cellular medicine and its treatment of pain and function associated with knee osteoarthritis

A first-of-its kind meeting brought leaders from eight orthopedic, sports medicine, pain management and regenerative medicine advocacy organizations together to discuss advancing cellular medicine in the U.S. The group of physicians, lawyers, engineers, PhDs, and CEOs from American Medical Society for Sports Medicine, Arthritis Foundation, Arthritis National Research Foundation, BoneSmart, Interventional Orthopedics Foundation, Regenerative Medicine Foundation and Regenerative Outcomes, realized the potential of combining forces to address: evidence-based data, FDA...

Learn More

News

01/10/20

Device and cellular therapy could lead to a major development in the treatment of pain and function associated with knee osteoarthritis for 14 million US adults

Individuals who overuse their joints, such as athletes, military members and people working physically demanding jobs are at a high risk of developing knee osteoarthritis (OA), according to the Arthritis Foundation. Unfortunately, there is no cure on the market for the 14 million US adults suffering.  Industry experts say patients undergo 966,000 total knee replacement surgeries (TKR) annually, millions of hyaluronic and corticosteroid injections, and take millions of pain medications...

Learn More

News

01/10/20

GID BIO aims to make treatment for pain and function associated with knee osteoarthritis accessible to millions with a single-use device and point-of-care therapy

Osteoarthritis (OA) of the knee is a painful disease that impacts 14 million U.S. adults. With no surgical or pharmaceutical treatment existing to cure the disease, industry experts say patients undergo 966,000 total knee replacement surgeries (TKR) annually, millions of hyaluronic and corticosteroid injections, and take millions of pain medications. The average cost of a TKR with included basic inpatient fees is around $57,000. This figure does not include pre-...

Learn More

News

01/9/20

Precision medicine could improve treatment for 14 million U.S. adults with knee osteoarthritis

Precision medicine — commonly referred to as personalized medicine — is widely recognized as the future of U.S. healthcare. Innovative treatment approaches can lead to affordable, minimally invasive therapies that lead to patients’ recovery from chronic conditions such as knee osteoarthritis, which affects 14 million US adults and is the main factor in 966,000 total knee replacements annually. For a chronic degenerative disease like osteoarthritis, reparative cells found in the...

Learn More

News

01/6/20

American Journal of Sports Medicine to publish results of a clinical trial

Trial measures safety and efficacy of device and point-of-care therapy; first to meet endpoints for reducing pain and improving function in osteoarthritic knees   In a shift toward minimally-invasive treatments for orthopedics, an influx of misinformation about stem cells leaves patients vulnerable to treatments that haven’t been approved by the Food and Drug Administration (FDA) and that promote false promises and potentially risky outcomes. American Journal of Sports Medicine (AJSM),...

Learn More